Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AbGn-7
- Development stage
- Phase 1
- Lead developer
- AbGenomics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AbGn-7 is a chimeric monoclonal antibody that targets a Lewis-A-like carbohydrate antigen (referred to as the AbGn-7 antigen) expressed on certain gastrointestinal cancer cells, including colorectal cancer. It has demonstrated immunomodulating and antineoplastic activities in preclinical studies, triggering apoptosis in colon cancer cells via a caspase-independent pathway and eliciting complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody was developed for potential use in treating colorectal cancer and other gastrointestinal malignancies. Its development was led by AbGenomics International[2][4].
02
Targets
AbGn-7 antigen (Lewis-A-like glycotope)
Beyond the preview
Go deeper on AbGn-7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbGn-7.